Melanoma
Conditions
Keywords
Stage IIIB, stage IIIC or stage IV melanoma, Progressive melanoma not responding to previous treatments
Brief summary
The objective of the present trial is to evaluate the local and general safety of the intratumoural electrotransfer of increasing doses of Plasmid AMEP in patients suffering from advanced or metastatic melanoma and to identify doses that could be effective on cutaneous lesions in man.
Detailed description
In this open, multicentre, dose escalation study, successive cohorts of 3 patients suffering from advanced or metastatic melanoma will be electrotransferred increasing doses of Plasmid AMEP into cutaneous melanoma lesions in 2 divided doses at one week interval.
Interventions
BIOLOGICALnaked DNA coding for protein AMEP
2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
Sponsors
Valerio Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Male or non-pregnant, non-breast feeding female; 2. Aged between 18 and 75 years; 3. Stage IIIB, stage IIIC or stage IV melanoma with: * At least 2 cutaneous or subcutaneous non necrotic accessible tumours; * Tumour size of 1 to 1.5 cm diameter; * No minimum distance between the 2 selected lesions; 4. Progressive melanoma not responding to previous treatments or patients refusing other therapies; 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2; 6. For women of child-bearing age: effective contraception method (oral contraception or intra-uterine device) used for more than 2 months before the 1st administration and to be maintained for 3 months after the last administration of Plasmid AMEP; 7. Having given a written informed consent.
Exclusion criteria
1. Patients who can benefit from other melanoma treatments including surgery; 2. Significant cardiac arrhythmias, electronic pacemakers, defibrillators, or any implanted electronic device; 3. Recent (less than 6 months) acute vascular diseases (stroke, MI…); 4. Advanced peripheral arterial diseases, venous ulcers, or scleroderma; 5. History or treatment of seizures within the last 5 years; 6. Clinically significant abnormality at pre-study full physical examination; 7. Any clinically significant ECG abnormalities; 8. Prior systemic therapy or any other antineoplastic treatments within the last 4 weeks, radiotherapy or surgery unrelated to the fields in question are allowed; 9. Abnormal renal function (creatinine plasma level \> ULN); 10. Abnormal liver function tests (any of the following): * PT \< 70%, ASAT, ALAT, alkaline phosphatases, GGT and/or total bilirubin \> ULN in the absence of liver metastasis; * PT \< 70%, ASAT, ALAT \> 2 ULN, alkaline phosphatases \> 1.5 ULN, GGT \> 5 ULN and/or total bilirubin \> 3 ULN in the case of liver metastases; 11. Abnormal bone marrow function: haemoglobin \< 10g/dL, WBC \< 3.109 /L and/or platelet count \< 100.103 /L; 12. Clinically significant abnormality in pre-study laboratory tests; 13. Evidence of significant active infection (e.g., pneumonia, wound abscess, etc); 14. Intractable coagulopathy; 15. Any significant disease, including psychiatric and dermatology diseases that may affect the proper evaluation of efficacy or safety; 16. Patients who had participated in another clinical trial in the last 30 days prior to enrolment in the present clinical trial; 17. Patients unwilling or unable to comply with protocol requirements and scheduled visits. Note: patients with brain metastases, or waiting for other therapies (i.e. isolated limb perfusion) may be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of Dose Limiting Toxicity defined as any grade 4 clinical, biological or any life-threatening ECG event occurring during the 9 weeks following treatment | 9 weeks |
Countries
Denmark, France, Slovenia
Outcome results
None listed